Biologic Drugs

Dec 19, 2017
By Pharmaceutical Technology Editors
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
Dec 19, 2017
By Pharmaceutical Technology Editors
Sanofi Genzyme and its partner, Alnylam Pharmaceuticals, have filed a marketing authorization application with EMA for an investigational RNAi therapeutic for treating a genetic-based disease.
Dec 18, 2017
By Pharmaceutical Technology Editors
The US Court of Appeals for the Federal Circuit has decided in favor of Novartis’ Sandoz in rendering the opinion that Amgen cannot use state laws to prohibit or delay the marketing of biosimilars.
Dec 14, 2017
By Pharmaceutical Technology Editors
Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.
Dec 14, 2017
By Pharmaceutical Technology Editors
FDA has approved a Pfizer biosimilar to J&J’s top-selling anti-inflammatory biologic, Remicade.
Dec 13, 2017
By Pharmaceutical Technology Editors
The companies will co-develop and co-commercialize the lead candidate generated from their earlier collaboration to treat genetic blood disorders.
Dec 13, 2017
By Pharmaceutical Technology Editors
In partnership with Indian pharmaceutical firm, Torrent Pharmaceuticals, Novo Nordisk has expanded an insulin manufacturing facility at Torrent’s Indrad, Gujarat, India site.
Dec 13, 2017
By Pharmaceutical Technology Editors
The approval for Admelog (insulin lispro injection) marks the first short-acting insulin approved as a “follow-on” product.
Dec 12, 2017
By Pharmaceutical Technology Editors
The agency has approved Nucala (mepolizumab) to treat Eosinophilic Granulomatosis with Polyangiitis (EGPA) to GlaxoSmithKline. This indication is the first FDA-approved therapy specifically to treat EGPA.
Dec 08, 2017
By Pharmaceutical Technology Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
native1_300x100
lorem ipsum